Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy

NCT02234180 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02234180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02234180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2014
Completion date
June 8, 2016
Enrollment
3 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, stage iib esophageal adenocarcinoma, stage iiia esophageal adenocarcinoma, stage iiib esophageal adenocarcinoma, stage iiic esophageal adenocarcinoma